{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-259481","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2026-06-05T20:00:16+00:00","discovered_at":"2026-06-05T20:01:00.408698+00:00","generated_at":"2026-06-05T20:01:28.561440+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Assembly Biosciences shareholders approve equity plan share increases; all director nominees elected","bullets":["Amendment No. 3 to 2018 Stock Incentive Plan approved; shares reserved increased from 1,478,333 to 2,678,333 (increase of 1,200,000).","Amendment No. 2 to Employee Stock Purchase Plan approved; shares reserved increased from 225,000 to 515,000 (increase of 290,000).","All nine director nominees elected: Altig, Cihlar, Consylman, Cook II, Houghton, Johnson-Pratt, Mahony, McHutchison, Okazaki.","Advisory say-on-pay approved (11,293,061 for, 5,401 against); ratification of Ernst & Young as auditor approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-259481","json":"https://secwatch.observer/filing/0001193125-26-259481.json","markdown":"https://secwatch.observer/filing/0001193125-26-259481.md","text":"https://secwatch.observer/filing/0001193125-26-259481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/asmb-20260604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:01:28.561440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"017eecd561a79d558d169c8b41091b479f59cc5f","claim":"ASSEMBLY BIOSCIENCES, INC. shareholders approved Election of nine directors to serve until the 2027 annual meeting at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders elected of the following to serve on the Company's Board of Directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Anthony E. Altig; Tomas Cihlar, Ph.D.; Gina Consylman; Robert D. Cook II; Sir Michael Houghton, Ph.D.; Lisa R. Johnson-Pratt, M.D.; Susan Mahony, Ph.D.; John G. McHutchison, A.O., M.D.; and Jason A. Okazaki.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"48f3be51e8b599b20f50ffaad38bdf52f410a69e","claim":"ASSEMBLY BIOSCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"ba1a466681f7a6ba9e7dbae05f3ac60652e1c5c0","claim":"ASSEMBLY BIOSCIENCES, INC. shareholders approved Approval of Amendment No. 3 to 2018 Plan to increase shares reserved by 1,200,000 at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders approved Amendment No. 3 to the 2018 Plan to increase the number of shares reserved for issuance under the 2018 Plan by 1,200,000 shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"f39dc27a53343a979e2906b2c9293e43f00ec3f2","claim":"ASSEMBLY BIOSCIENCES, INC. shareholders approved Approval of ESPP Amendment No. 2 to increase shares reserved to 515,000 at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders approved the ESPP Amendment No. 2 to increase the number of shares reserved under the ESPP to 515,000 shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"f70aebdf6c29cbb15a87076e1aa4fe824c2b3a79","claim":"ASSEMBLY BIOSCIENCES, INC. shareholders approved Advisory vote on named executive officers' compensation at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders approved, on a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526259481/0001193125-26-259481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}